4 recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 4 |
| Phase 2 | 1 | Recruiting 1 |
Follow Synovial Sarcomas: new trials by email Literature Review of Synovial Sarcomas trials Research Report on Synovial Sarcomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine - Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Zelluna Immunotherapy AS | 9 | 2026-05-11 | 2026-09-04 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| AOH1996 for the Treatment of Refractory Solid Tumors PCNA Inhibitor AOH1996 - Refractory Malignant Solid Neoplasm, Osteosarcoma | Phase 1 | Recruiting | City of Hope Medical Center | 92 | 2022-09-08 | 2026-10-20 |
Sarcoma, Synovial (4) · Osteosarcoma (2) · Ovarian Neoplasms (2) · Recurrence (2) · Adrenal Cortex Neoplasms (1) · Adrenal Gland Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Ependymoma (1) · Esthesioneuroblastoma, Olfactory (1) · Glioblastoma (1) · Glioma (1) · Head and Neck Neoplasms (1) · Leiomyosarcoma (1) · Medulloblastoma (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Sarcoma (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Adnexal Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2)
Cyclophosphamide (1) · fludarabine (1) · lutetium Lu 177 dotatate (1) · olaparib (1) · venetoclax (1)
City of Hope Medical Center (1) · Fundación de investigación HM (1) · Treeline Biosciences, Inc. (1) · Zelluna Immunotherapy AS (1)
Australia (1) · Spain (1) · United Kingdom (1) · United States (1)
Marta Osuna Marco, PhD (1) · Padma Yerramilli-Rao, MB BS, PhD (1) · Vincent Chung, MD (1)
P30CA033572 (1)